Need Some Help?
We can help you find the information that meets your research needs.
Please call us at
+886 2 27993110
+65 90752357
+60 12 7220722
or send an email to us at mi@hintoninfo.com
IHS_EWBIEEE xploreIHS_EWB_GF

Biomarker Technology Platforms for Cancer Diagnoses and Therapies

  • LinkedIn
  • facebook
  • Twitter
Published: 2011/09/01
Page: 342
Format: PDF
Price:
USD 3,400 (Single-User License)
USD 6,800 (Multi-User License)
USD 10,200 (Global-User License)
線上訂購或諮詢
Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. The purpose of this TriMark Publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. This study particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor’s offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer.
Back